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http://dx.doi.org/10.1016/j.stemcr.2017.02.006SUMMARYHuman stem cell models have the potential to provide platforms for phenotypic screens to identify candidate treatments and cellular
pathways involved in the pathogenesis of neurodegenerative disorders. Amyloid precursor protein (APP) processing and the accumula-
tion of APP-derived amyloid b (Ab) peptides are key processes in Alzheimer’s disease (AD). We designed a phenotypic small-molecule
screen to identify modulators of APP processing in trisomy 21/Down syndrome neurons, a complex genetic model of AD. We identified
the avermectins, commonly used as anthelmintics, as compounds that increase the relative production of short Ab peptides at the
expense of longer, potentially more toxic peptides. Further studies demonstrated that this effect is not due to an interaction with the
core g-secretase responsible for Ab production. This study demonstrates the feasibility of phenotypic drug screening in human stem
cell models of Alzheimer-type dementia, and points to possibilities for indirectly modulating APP processing, independently of g-secre-
tase modulation.INTRODUCTION
As the burden of neurodegenerative disease on an aging
population increases, it is striking to note that there
remain no approved disease-modifying treatments for de-
mentia. Drug discovery in this area has been challenging,
as while there has been undeniable progress, our under-
standing of the biology and mechanisms underpinning
these complex conditions still remains limited. The advent
of reprogramming technology in human cells (Takahashi
et al., 2007; Takahashi and Yamanaka, 2006) has enabled
the generation of patient-derived neurons from accessible
somatic cells of individuals carrying genetic forms of
neurodegenerative diseases. The ability to recapture path-
ological processes in disease-affected neuronal types
derived from individuals with genetic forms of disease
has been demonstrated in a number of conditions,
including motor neurons in spinal muscular atrophy
(Ebert et al., 2009), dopaminergic midbrain neurons in
Parkinson’s disease (Sanchez-Danes et al., 2012), and
cortical neurons in Alzheimer’s disease (AD) (Israel et al.,
2012; Shi et al., 2012b; Yagi et al., 2011). Using cellular
phenotypes reproduced in appropriate human cell types,
it is now possible not only to study fundamental disease
biology but also to identify disease-modifying pathways
using genetic or pharmacological phenotypic screening870 Stem Cell Reports j Vol. 8 j 870–882 j April 11, 2017 j ª 2017 The Auth
This is an open access article under the CC BY license (http://creativecommoin a relevant biological context. We report here a pheno-
typic screen of small molecules in cortical neurons with
a genetic form of AD, performed with the aim of identi-
fying compounds modifying the production of amyloid
b (Ab), an aggregation-prone and toxic peptide central to
AD pathology.
The amyloid cascade hypothesis of AD proposes that
accumulation and deposition of Ab peptides, derived
from the proteolytic processing of amyloid precursor
protein (APP), is central to the development of AD
(Hardy and Allsop, 1991; Hardy and Higgins, 1992).
While AD commonly presents sporadically later in life
(sAD), evidence for the amyloid hypothesis was drawn
from observations that rare autosomal dominant missense
mutations in the genes encoding APP, or presenilin 1
(PSEN1) or 2 (PSEN2), which form the catalytic region
of the g-secretase complex responsible for proteolytic
cleavage of APP into Ab peptides, lead to highly penetrant
familial forms of early-onset AD (fAD) (Ertekin-Taner,
2007). Increased expression of the APP gene, due either
to duplication of the APP locus (APPdup) (Rovelet-Lecrux
et al., 2006; Sleegers et al., 2006), or trisomy of chromo-
some 21 (Rumble et al., 1989)—containing the APP
gene—in Down syndrome (trisomy 21 [TS21]), also
leads to increased production and accumulation of Ab
peptides and the early onset of AD pathology. While theors.
ns.org/licenses/by/4.0/).
mechanistic link between Ab accumulation and neuronal
dysfunction in both fAD and sAD remains unclear, target-
ing the processing of APP and the production of Ab
within the framework of the amyloid hypothesis has re-
mained an attractive approach for AD drug discovery in
recent years.
It has been proposed that the dynamic balance be-
tween longer, more toxic Ab peptides, in particular the
42-amino-acid Ab42, and shorter Ab peptides is a more
significant determinant of disease initiation and progres-
sion than total Ab production (Findeis, 2007; Kuperstein
et al., 2010). This suggests that modulating rather than
inhibiting processing may be an effective strategy while
avoiding adverse effects due to altered proteolysis of
other substrates of g-secretase. After initial b-secretase
cleavage, the remaining membrane-bound fragment of
APP is subjected to endopeptidase and then stepwise
carboxypeptidase cleavage by g-secretase, generating pro-
gressively shorter Ab peptides (Takami et al., 2009). By
augmenting the carboxypeptidase efficiency of g-secre-
tase with g-secretase modulators (GSMs), it is possible
to shift the production of Ab peptides away from longer
more toxic species toward shorter forms, without
affecting total Ab production or g-secretase targeting of
other substrates. While the results of larger clinical trials
are yet to be reported, GSMs have demonstrated target
engagement in patients (Soares et al., 2016; Toyn et al.,
2016; Yu et al., 2014) and remain a promising avenue
for development.
APP has a complex life cycle: in addition to its pro-
cessing by b- and g-secretase, it undergoes proteolytic
turnover in a number of different cellular compartments
by numerous different proteases (Small and Gandy,
2006). This complexity suggests that it may be possible
to alter amyloidogenic APP processing in a secretase-inde-
pendent manner to shift Ab peptide production toward
shorter forms, at the expense of production of longer,
toxic peptides. The aim of this study was to ask whether
it was possible to identify secretase-independent, small
molecule modulators of Ab processing that would shift
the production of Ab fragments in human cortical neu-
rons away from Ab42 to shorter, non-toxic forms. To do
so, we performed a small-molecule phenotypic screen in
TS21 cortical neurons, which we have previously shown
to produce highly elevated levels of Ab peptides (Shi
et al., 2012b). Using this approach, we identified a family
of macrocyclic lactone anthelminthic compounds, the
avermectins, which reproduce the effects of GSMs,
without acting directly on the g-secretase complex or
causing accumulation of g-secretase substrates. These
data demonstrate that phenotypic screening in human
stem cell models of AD provides a potentially powerful
strategy for identifying disease-modifying pathways andcompounds, independent of known approaches to modu-
lating APP processing.RESULTS
A Primary Phenotypic Screen Identifies Modifiers of
Ab Production
To identify small-molecule modifiers of Ab production in
human neurons, we performed a phenotypic screen in
cortical neurons differentiated from TS21 induced plurip-
otent stem cells (iPSCs) cultured in 96-well plates (Fig-
ure 1). Neurons derived from this genetic background
overproduce all Ab peptides (Shi et al., 2012b), and thus
provide a sensitized background for drug screening in
this context. A single-point screen of the Prestwick
Chemical library was performed at 1 mM, with drugs and
media refreshed at 48-hr intervals. Extracellular medium
collected after 4 days of drug treatment was analyzed by
multiplexed immunoassay to assess concentrations of
Ab38, Ab40, and Ab42. The activity of lactate dehydroge-
nase (LDH) in extracellular medium collected after
6 days of treatment was used as an indicator of cellular
toxicity. The aim of this study was to identify compounds
that shift APP processing away from the production of
longer, potentially toxic forms of Ab, specifically Ab42,
as indicated by increases in the ratio of Ab38/Ab42 and/
or Ab40/Ab42.
To evaluate the assay performance within each plate, we
calculated thecoefficientofvariation (CV)ofDMSOcontrols
(n = 5 cultures/plate) for each outcome measure. Mean CVs
for Ab38/Ab42 and Ab40/Ab42 ratios in DMSO control-
treated cultureswere 9.12%and 7.58%, respectively (Figures
1C and 1E). These results indicate a low level of variation for
calculated Ab ratios in control conditions, and a stable plat-
form for the identification of hit compounds.
A control-independent method, implemented using
the open-source Bioconductor cellHTS2 package (Boutros
et al., 2006), was used to identify hit compounds, with
the B-score adjustment used to correct for positional differ-
ences within the 96-well plates (Brideau et al., 2003). After
excluding 73 compounds for increased LDH activity
(B score >3), 55 compounds were identified that reduced
the relative contribution of Ab42 to total Ab production
(B score >3 for increased Ab38/Ab42 ratio and/or Ab40/
Ab42 ratio). A validation screen was subsequently per-
formed whereby hit compounds were tested again at
1 mM in triplicate, and their ability to reproduce their initial
effect was confirmed either by a significant Fisher’s least
significant difference test or at least two of three replicates
reproducing a >10% increase in the Ab38/Ab42 or Ab40/
Ab42 ratio compared with DMSO treatment. Validated
hits were tested for dose response, and two compoundsStem Cell Reports j Vol. 8 j 870–882 j April 11, 2017 871
Figure 1. Phenotypic Screen of the Pre-
stwick Chemical Library for Modifiers of
Ab Production in TS21 Cortical Neurons
(A) Fifty days after the initiation of neural
induction, cortical neurons differentiated
from TS21 iPSCs express microtubule-associ-
ated protein 2 (MAP2), and the cerebral cor-
tex neuronal markers CTIP2 and TBR1.
Scale bar represents 50 mm.
(B) Timeline of the primary screen of the
Prestwick Chemical library in TS21 iPSC-
derived cortical neurons. d, day.
(C and E) Coefficients of variation (CV) for
vehicle (DMSO)-treated cultures for (C)
Ab38/Ab42 and (E) Ab40/Ab42 ratios indi-
cate a stable and sensitive platform for
identifying hit compounds (dashed line rep-
resents recommended upper limit of 15%
[Inglese et al., 2007]).
(D and F) A primary screen of the Prestwick
Chemical library (black symbols) identified a
number of primary hits (blue symbols)
altering the Ab38/Ab42 (D) and Ab40/
Ab42 (F) ratios (dashed line represents
B-score >3). Primary hits were validated in
a secondary screen (green symbols) and
then confirmed with a dose response (red
symbols).were confirmed as hits based upon their ability to increase
the ratio of Ab38 to Ab42 in a dose-dependentmanner (Fig-
ure 1D). This resulted in an overall hit rate of 0.167% from
the Prestwick Chemical library.
Avermectins Alter the Ab38/Ab42 Ratio in Human
Cortical Neurons
In TS21 cortical neurons, we found that the previously
described non-steroidal anti-inflammatory drug (NSAID)-
derived GSM (R)-flurbiprofen (Figure 2A) and the imid-
azole-based GSM E2012 (Figure 2B) both increased the
Ab38/Ab42 ratio in a dose-dependent manner (F(7, 16) =
43.77, p < 0.0001; F(7, 16) = 1633, p < 0.0001, respectively).
In amanner analogous to the knownGSMs, one compound
identified in the primary screen, abamectin (Figure 2C),
demonstrated a marginal increase in the ratio of Ab38 to
Ab42 (F(5, 15) = 2.754, p = 0.0586), while a structurally related872 Stem Cell Reports j Vol. 8 j 870–882 j April 11, 2017compound in the library, ivermectin (Figure 2D), signifi-
cantly increased the Ab38/Ab42 ratio in a dose-dependent
manner (F(5, 15) = 4.435, p = 0.0221). These two compounds
are members of the avermectin chemical class of macrocy-
clic lactones, and have been used for decades as anthelmin-
tics to treat parasitic infections in animals and humans, but
do not efficiently cross the blood-brain barrier (Fisher and
Mrozik, 1992).
To determine whether the effect on the Ab38/Ab42 ratio
was a common property across the avermectin family, we
assessed two related compounds. Emamectin benzoate
(Figure 2E) had a similar, moderate effect (F(5, 15) = 6.284,
p = 0.0050), whereas selamectin (Figure 2F) exhibited
higher potency on the Ab38/Ab42 ratio (F(5, 15) = 16.18,
p = 0.0003). The effect appears to be specific to the aver-
mectin family, as moxidectin (Figure 2G), a member
of the closely related milbemycin class of macrocyclic
Figure 2. Avermectins Increase the Ab38/
Ab42 Ratio in Human TS21 Neurons, in a
Manner Phenotypically Similar to Previ-
ously Identified g-Secretase Modulators
The g-secretase modulators (R)-flurbiprofen
(A) and E2012 (B) dose-dependently increase
the ratio of Ab38 to Ab42 in human TS21
cortical neurons. The avermectins abamectin
(C) and ivermectin (D), identified in the pri-
mary screen, as well as emamectin benzoate
(E) and selamectin (F), also dose-depen-
dently increase the Ab38/Ab42 ratio, while
the structurally related milbemycin mox-
idectin (G) has no consistent effect. n = 3–6
cultures/concentration. Error bars represent
SD. Note that abamectin, ivermectin, and
emamectin benzoate are all mixtures of B1a
(R = CH2CH3) and B1b (R = CH3) components.lactones, had no consistent effects on this ratio, despite its
greater water solubility allowing for much higher concen-
trations to be achieved (H(5) = 11.77, p = 0.0380; however,
for all post hoc comparisons p > 0.05).
All avermectins increased the Ab38/Ab42 ratio by
increasing Ab38 and/or reducing Ab42 (Figures 3A and
3C), while some had additional effects on Ab40 (Figure 3B).
Abamectin, ivermectin, and selamectin all caused a signif-
icant increase in Ab38 (F(5, 15) = 6.543, p = 0.0040; F(5, 15) =
13.05, p = 0.0003; H(5) = 16.59, p = 0.0053, respectively),
while emamectin benzoate and selamectin caused a signif-
icant decrease in Ab42 (F(5, 15) = 5.889, p = 0.0033; F(5, 15) =
7.22, p = 0.0039, respectively). In addition, abamectin, iver-
mectin, and selamectin all caused a significant decrease in
Ab40 (F(5, 15) = 6.063, p = 0.0058; H(5) = 12.35, p = 0.0303;
F(5, 15) = 53.38, p = 0.0003, respectively).
As macrocyclic lactones have a high lipophilicity, we
considered whether the effects of avermectins on Ab pro-
duction were due to non-specific perturbations of the
membrane and/or g-secretase-APP interaction. Previously
reported cLogP values (Prichard et al., 2012) indicate nocorrelation between lipophilicity and efficacy for the com-
pounds studied: the largely inactive milbemycin moxidec-
tin and the most potent avermectin selamectin share com-
parable cLogP values of 6 and 6.3, respectively, while the
moderately active avermectins abamectin and ivermectin
have reported cLogP values of 5.3 and 4.8, respectively (Pri-
chard et al., 2012). Given that these observations strongly
suggest that the modulation of Ab production by the
avermectins is not a simple function of their relative lipo-
philicity, we performed a number of experiments to iden-
tify possible molecular targets.
Avermectins Have Complex Effects on APP Processing
and Ab Peptide Production
The Ab38/40/42 immunoassay captures only a fraction of
Ab peptides secreted from human neurons. As the analysis
of these three peptides indicated that the avermectins
exhibit complex effects on APP proteolysis, extracellular
medium was analyzed with an approach combining immu-
noprecipitation andmatrix-assisted laser desorption/ioniza-
tion (IP-MALDI) to assess a wider spectrum of Ab peptides.Stem Cell Reports j Vol. 8 j 870–882 j April 11, 2017 873
Figure 3. The Avermectin-Induced Increase in the Ab38/Ab42
Ratio Is Driven by an Increase in Ab38 and/or a Decrease
in Ab42
(A and C) When the contribution of each Ab species is considered as
a percentage of total as detected by immunoassay, avermectins
cause a dose-dependent increase in Ab38 (A) and/or a decrease in
Ab42 (C).
(B) With the exception of emamectin benzoate, the avermectins
also cause a dose-dependent decrease in Ab40 levels (B).
n = 3–6 cultures/concentration. Error bars represent SD.It has previously been shown that Ab1-14, Ab1-15,
and Ab1-16 are increased and Ab1-34 decreased following
treatment with a g-secretase inhibitor (GSI) (Portelius
et al., 2010a, 2012), while treatment with GSM leads to
an increase in Ab1-37 together with decreases in Ab1-39,874 Stem Cell Reports j Vol. 8 j 870–882 j April 11, 2017Ab1-40, and Ab42 (Portelius et al., 2010b, 2014). Based
on these previous studies and the immunoassay results of
this study, the following peptides were preselected for
quantification: Ab1-14, Ab1-15, Ab1-16, Ab1-34, Ab1-37,
Ab1-38, Ab1-39, and Ab1-40. Ab1-42 was deliberately
excluded for analysis, as it was not reliably detected and
quantifiable in all samples.
Treatment of TS21 neurons with selamectin (1.5 mM), the
most potent of the avermectins, over 10 days resulted in an
increase in Ab1-37 and a decrease in Ab1-40, with limited
effects on Ab1-14, Ab1-15, and Ab1-16 (Figures 4A–4C).
An increase in Ab1-37 and a decrease in Ab1-40 is consis-
tent with g-secretase modulation (Portelius et al., 2010b),
while a limited effect on Ab1-14, Ab1-15, and Ab1-16 sug-
gests minimal inhibition of g-secretase function (Portelius
et al., 2010a, 2012). It is noteworthy that the avermectin-
induced increase in Ab38 detected with the Ab38/40/42
immunoassay was not detected with the IP-MALDI
approach. This finding is not particularly unexpected,
however; it has previously been shown that the GSM
E2012 has no significant effect on Ab38 by IP-MALDI (Por-
telius et al., 2010b), yet we detected a robust increase in
Ab38/Ab42 with this compound using immunoassay
detection (Figure 2B), largely driven by increases in Ab38.
While IP-MALDI is capable of detecting a wider range of
Ab peptides, it is not always as sensitive or quantitative
as immunoassay approaches across all peptide species,
particularly for low-abundance and relatively hydrophobic
peptides.
The Effect of Avermectins on Ab Production Is
Independent of Their Known Pharmacology
The highest affinity targets for avermectins are invertebrate
glutamate-gated chloride channels. Acting as irreversible
agonists at these ion channels, avermectins stabilize the
open conformation, admitting the flow of negatively
charged chloride ions into cells, paralyzing nematodes
and parasites (Wolstenholme and Rogers, 2005). Despite
usual exclusion from the mammalian CNS, avermectins
also have affinity for themammalian ligand-gated chloride
channels g-aminobutyric acidA (GABAA) and glycine,
acting as positive allostericmodulators anddirect partial ag-
onists at nanomolar concentrations (Dawson et al., 2000;
Shan et al., 2001). To determine whether the effects on Ab
productionwere due to activity atGABAA and/or glycine re-
ceptors, we assessed whether the effects of avermectins
couldbephenocopiedor antagonizedwith specific agonists
and antagonists of these receptors, respectively (Figure 5).
The effects of an ascending concentration of the GABAA
receptor antagonist picrotoxin (0.3–100 mM) on the Ab38/
Ab42 ratio were tested in the absence or presence of the
twomost potent avermectins identified in this system; iver-
mectin (1 mM) and selamectin (1 mM) (Figure 5A). Two-way
Figure 5. Avermectins Do Not Influence Ab Processing via Their
Known Pharmacological Targets
(A and B) The effects of ivermectin and selamectin are not blocked
by the GABAA receptor antagonist picrotoxin (A) and are not
phenocopied by the GABAA receptor agonist muscimol (B).
(C) Likewise, the glycine receptor antagonist strychnine exhibited
no dose-dependent antagonism of avermectin effects of Ab pro-
cessing (see also Figure S1).
n = 3–6 cultures/treatment. Error bars represent SD.
Figure 4. Selamectin Has Complex Effects on Ab Peptide Pro-
duction as Measured with IP-MALDI
(A and B) Representative Ab IP-MALDI traces after treatment with
DMSO vehicle (A) and selamectin (B). Peptides selected for quan-
titative analysis are highlighted in red.
(C) Analysis of peak areas of selected peptides as a percentage of
total peak areas indicates an increase in Ab1-37 and a decrease in
Ab1-40 following selamectin treatment.
n = 4 cultures per treatment. Error bars represent SD.ANOVA revealed significant main effects of the avermec-
tins (F(2, 41) = 176.8, p < 0.0001) and picrotoxin (F(5, 41) =
9.996, p < 0.0001). Crucially, however, there was no signif-
icant interaction between picrotoxin and the avermectins
(F(10, 41) = 0.8645, p = 0.5724). Additionally the potent
GABAA receptor agonistmuscimol (Figure 5B) had no effect
on the Ab38/Ab42 ratio when tested up to 100 mM (F(6, 17) =
2.007, p = 0.1209).Similarly, two-way ANOVA of ascending concentrations
of the glycine receptor antagonist strychnine (0.3–30 mM)
in the presence and absence of these avermectins (both
tested at 1 mM) revealed a significant main effect of
avermectins (F(2, 41) = 43.55, p < 0.0001) and strychnine
(F(5, 41) = 4.055, p = 0.0044), but again no significant inter-
action between strychnine and the avermectins (F(10, 41) =
0.6173, p = 0.7901). In addition, no inhibition of the
concentration-dependent effect of ivermectin or selamec-
tin on the Ab38/Ab42 ratio is observed when dose response
is performed in the presence of strychnine (Figure S1).Stem Cell Reports j Vol. 8 j 870–882 j April 11, 2017 875
Figure 6. Avermectins Do Not Cause Accumulation of C-terminal Fragments of g-Secretase Substrates, and Their Effects on Ab Are
Not Due to Direct Action on the Core g-Secretase Complex
(A) In human cortical neurons, treatment with the conventional GSI DAPT causes significant accumulation of C-terminal fragments of
the g-secretase substrates APP and N-cadherin, whereas treatment with the milbemycin moxidectin or the avermectins ivermectin or
selamectin does not (see also Figure S2).
(B) In a cell-free g-secretase assay, the conventional GSI L-685,458 inhibits cleavage of APP C-terminal fragment by g-secretase, and
reduces the production of AICD.
(C) Moxidectin and the avermectins have no consistent effects, although 1 mM ivermectin causes a significant reduction of AICD pro-
duction (C).
(D–F) In the same assay, milbemycins and avermectins induce no dose-dependent changes in the production of Ab38 (D), Ab40 (E), or
Ab42 (F) over DMSO control.
Western blots in (A) and (B) are representative of two to four cultures per treatment (A) and three independent experiments (B),
respectively, and data shown in (C) to (F) are from three independent experiments. Error bars represent SD. *p < 0.05, Holm-Sı´da´k adjusted
one-sample t test versus 100% control value.These results do not support the hypothesis that the aver-
mectins are working via their known mammalian targets,
the GABAA or glycine receptors, to affect Ab processing.
Avermectins Do Not Cause Accumulation of
g-Secretase Substrates, and Do Not Directly Interact
with the g-Secretase Complex to Effect Changes in Ab
Production
One of the positive aspects of existing GSMs is that they do
not cause the accumulation of the C-terminal fragments of
APP or other g-secretase substrates that is commonly
observed following g-secretase inhibition. Analysis of
drug-treated TS21 cortical neurons revealed that, while
the conventional GSI DAPT (1 mM) causes accumulation876 Stem Cell Reports j Vol. 8 j 870–882 j April 11, 2017of APP andN-cadherin C-terminal fragments, neithermox-
idectin (10 mM) nor the avermectins ivermectin (1.5 mM) or
selamectin (1.5 mM) had the same effect (Figure 6A), sug-
gesting little inhibition of g-secretase function. Chronic
treatment over 30 days with the same compounds had
similar effects, although ivermectin caused a mild accumu-
lation of N-cadherin C-terminal fragment over this pro-
tracted treatment time (Figure S2).
A cell-free assay was performed to test whether avermec-
tins act directly on the core g-secretase complex to effect
changes in Ab processing (Figures 6B–6F). When C99-
33FLAG is introduced as a substrate in this system,
efficiency of endopeptidase cleavage is assessed via the
production of APP intracellular domain (AICD)-33FLAG
Figure 7. The Effect of Selamectin on Ab Production in Cortical
Neurons Is Reversible and Not Specific to the TS21 Genotype
(A) After 10 days of compound treatment, withdrawal of selamectin
leads to a reduction in effect compared with continued treatment
over 4 days (A).
(B) The effect of selamectin on Ab processing is reproduced in
neurons differentiated from patients carrying APP or PSEN1 muta-
tions, indicating that the effect is not specific to the TS21 geno-
type (B).
n = 3–6 cultures/treatment. Error bars represent SD.measured by western blot, while the downstream produc-
tion of Ab species by sequential carboxypeptidase activity
is measured by immunoassay (Chavez-Gutierrez et al.,
2012; Szaruga et al., 2015). We utilized the prototypical
g-secretase inhibitor L-685,458 as a positive control for
inhibited endopeptidase cleavage, which is reflected by
a reduced production of AICD-33FLAG (Figure 6B). The
inactive milbemycin moxidectin and the two avermectins
with the most potent effects on Ab processing in a whole-
cell system, selamectin and ivermectin, exhibited no signif-
icant dose-dependent effects onAICD-33FLAGproduction
(Figures 6B and 6C), although ivermectin exhibited a
significant 10% reduction in AICD production at 1 mM
(t(2) = 18.54; p = 0.0258). Likewise, none of themacrocyclic
lactone compounds had any appreciable effect on Ab38
(Figure 6D), Ab40 (Figure 6E), or Ab42 (Figure 6F) produc-
tion in this cell-free system (all one-sample t tests or
Wilcoxon signed-rank tests p > 0.05 compared with 100%control values), despite strong effects in a whole-cell sys-
tem at lower concentrations (see above). These findings
indicate that the effects of avermectins on Ab processing
are not via direct action on the core g-secretase complex.Avermectin Effects on Ab Production Are Reversible
and Not Specific to TS21 Neurons
To determine whether the effects of selamectin on Ab
production were reversible, we performed a washout
experiment whereby exposure to drug was discontinued
after chronic treatment. After 10 days of continuous expo-
sure, DMSO or 1.5 mM selamectin treatment was either
continued or, in the washout condition, withdrawn and re-
placed with neural cell-culture medium alone (Figure 7A).
Over the course of 10 days, selamectin increased the
Ab38/Ab42 ratio compared with DMSO vehicle treatment.
When treatment was withdrawn, however, the Ab38/Ab42
ratio in selamectin-treated neurons returned almost to
vehicle-treated levels over the course of 4 days. These obser-
vations suggest that the effect of selamectin is at least
partially reversible over this timescale.
The overexpression of genes on chromosome 21 other
than APP is thought to contribute to the AD-like pathology
observed in Down syndrome (Wiseman et al., 2015). To
determine whether the effect of avermectins on Ab produc-
tion was specific to the TS21 genotype, or whether aver-
mectins could alter APP processing in other genetic forms
of AD, we tested selamectin in cortical neurons derived
from iPSCs from a healthy control (non-diseased control
[NDC]), and patients carrying an APP duplication (APPdup),
an APP missense mutation (APP V717I), or a Presenilin-1
mutation (PSEN1M146I) (Figure 7B).
Selamectin increased the ratio of Ab38 to Ab42 in a dose-
dependent manner in neurons from patients carrying
APPdup (F(4, 12) = 8.741, p = 0.0015), APP V717I (F(5, 12) =
38.09, p < 0.0001), and PSEN1 M146I (F(5, 15) = 16.8,
p < 0.0001) mutations, but not in neurons from a non-
diseased background (H(4) = 9.208, p = 0.0561). This differ-
ence is likely due to the fact that data from thenon-diseased
control line were not normally distributed and were
analyzed non-parametrically, as using the more powerful
parametric analysis does reveal an effect in this genetic
background (F(4, 12) = 5.532, p = 0.0092). These findings
together suggest that the effect of the avermectins is gener-
alizable, and not limited to the TS21 genotype or reliant
upon increase in APP copy numbers and protein levels.DISCUSSION
We report here the identification, by phenotypic screening
in a human stem cell model of AD, of g-secretase-indepen-
dent modulators of APP processing. A class of anthelminticStem Cell Reports j Vol. 8 j 870–882 j April 11, 2017 877
macrocyclic lactones, the avermectins, increases the relative
production of short formsofAb and reduces the relative pro-
duction of longer Ab fragments in human cortical neurons.
This effect is independent of the knownmolecular targets of
avermectins in the mammalian nervous system and, more-
over, despite an effect phenotypically similar to that of
existing GSMs, is not due to a direct interaction with the
core g-secretase complex. The avermectins phenocopy
g-secretase modulation in healthy control neurons and
multiple different models of genetic forms of AD, including
TS21, APP duplication, and PSEN1 and APP mutations. In
addition to the discovery of avermectins as modifiers of
Ab peptide production, this study demonstrates the utility
of human stem cell models for small-molecule phenotypic
screens of disease-relevant biology in neurodegeneration.
Future investigation will focus on elucidating the mecha-
nisms and molecular targets behind this phenomenon.
The effect of the avermectins on Ab production mimics
that of GSMs, a diverse class of compounds that, either
through action on g-secretase or APP, alters APP cleavage
in favor of shorter Ab peptides. With a phenotypic effect
opposite to that of the PSEN1 mutations leading to early-
onset fAD, which drives an accumulation of longer Ab pep-
tides due to impaired carboxypeptidase cleavage efficiency
of g-secretase (Chavez-Gutierrez et al., 2012), the promise
of GSMs lies in their ability to reduce the accumulation of
toxic longer forms of Ab while preserving g-secretase cleav-
age of its other substrates. Of note, the very first GSMs were
NSAIDs, whose effect on increasing Ab38 while reducing
Ab42 production was first discovered thorough a pheno-
typic screen in transfected cells and ascribed to a mecha-
nism independent of their previously knownmolecular tar-
gets (Weggen et al., 2001). Target identification of the early
GSMs has led to more potent and selective derivatives, a
number of which are currently in human trials for AD
(Hall and Patel, 2014).We have demonstrated that the aver-
mectins elicit changes inAb production that are comparable
with those in existing GSMs, and similarly avoid accumula-
tion of g-secretase substrates, but act through a g-secretase-
independent pathway. It is hoped that target identification
in future studies may lead to derivatives with higher po-
tency, in addition to more favorable physicochemical and
pharmacokinetic properties than the existing avermectins,
which are highly lipophilic (Prichard et al., 2012) and
poorly CNS penetrant (Schinkel et al., 1994).
While the results of the membrane-based g-secretase
assays are not consistent with a direct effect on the core
g-secretase complex, there are indirect ways by which APP
proteolysis may be altered that could go undetected in a
cell-free assay. The specific APP processing paths leading to
the generation of different Ab species are determined by
the dynamic shuttling between intracellular compartments
of the membrane-bound substrates and the secretases,878 Stem Cell Reports j Vol. 8 j 870–882 j April 11, 2017which must co-localize for proteolysis to occur (see review
by Small and Gandy, 2006). These shuttling processes are
amenable to pharmacological intervention, and indeed it
was recently shown that small-molecule stabilization of
the neuronal retromer complex, which traffics APP from en-
dosomes to theGolgi, limits co-localizationofAPPandb-sec-
retase in theendosomalmembrane, thuscausinga reduction
in total Ab peptide production (Mecozzi et al., 2014).
More broadly, this study confirms the feasibility of unbi-
ased phenotypic drug screening for modifiers of neurolog-
ical disease in patient-derived neurons; an approach that
has been a core aim of this technology since its inception
(Khurana et al., 2015). In the small number of phenotypic
drug screens in human stem cell models of neurodegenera-
tion reported thus far, smallmolecules have been identified
which rescued downregulated proteins in familial dysauto-
nomia (Lee et al., 2012) and inhibited aberrant protein
aggregation in amyotrophic lateral sclerosis (Burkhardt
et al., 2013). Cortical neurons derived from patients
carrying fAD mutations or more complex forms of AD,
including TS21, faithfully reproduce pathological changes
in disease-relevant proteins reported in vivo, without the
need for artificial overexpression or exogenous toxic insult
(Israel et al., 2012; Moore et al., 2015; Shi et al., 2012b; Yagi
et al., 2011). Not only has this system previously provided
mechanistic insight into AD initiation and progression
(Moore et al., 2015), but we have demonstrated here that
the aberrant changes in Ab production in AD human neu-
rons provide a sensitized and relevant background for unbi-
ased phenotypic screening, in amodel system that is repro-
ducible, scalable, and responsive to existing modulators of
Ab production. While cell-based phenotypic screens have
traditionally utilized immortalized cell lines or overexpres-
sion systems, the ability to derive disease-relevant cell types
from reprogrammed human cells is likely to be of addi-
tional benefit for phenotypic assays in neurodegenerative
diseases, due to the high degree of cell-type- and cell-sub-
type-specific pathology (Mattson and Magnus, 2006).
The two main avenues for the discovery and develop-
ment of new medicines are target-based screening and
cell-based phenotypic screening. In the first, a molecular
target of interest in the disease is defined and validated
prior to the screen, whereas in the second the phenotype
of interest is screened for modifiers of which their underly-
ing molecular mechanism of action is not yet known.
While early drug discovery was almost entirely based on
screening against known phenotypes, more recent ad-
vances in genomics and improved understanding of the
molecular mechanisms underlying disease have shifted
the focus toward more target-based approaches. However,
the complex andmultifactorial nature of human disorders,
particularly those of the CNS, has hampered identification
of relevant and specific singular drug targets, and perhaps
explains why phenotypic screening still contributes to a
greater proportion of first-in-class drugs (Swinney and
Anthony, 2011). The lack of assumptions with a pheno-
typic approach alsomeans there is the potential to uncover
novel disease pathways. It has been argued that an initial
approach using empirical phenotypic assays followed by
hypothesis-driven target identification might provide an
optimum combination of techniques for the identification
and development of new treatments for complex human
disorders (Swinney, 2013). Combined with the ability to
derive disease-specific cell types from reprogrammed
patient cells, phenotypic screening is once again in the
spotlight as a powerful tool in the search for disease-modi-
fying treatments.
Using cortical neurons derived from an individual with
TS21, a common complex genetic form of AD, we demon-
strated the feasibility of phenotypic, small-molecule screens
in human stem cell models of AD.We identified the anthel-
minthic avermectins as modulators of Ab production,
which act independently of g–secretase to alter APP process-
ing inmanner similar to g–secretasemodulation. The recent
emergence and continued development of human cell
models of disease in combination with traditional pheno-
typic screening approaches promises to allow the identifica-
tion of potential drug candidates in addition to uncovering
new pathways underlying disease pathology.EXPERIMENTAL PROCEDURES
Cell Culture
Primary screeningandmechanistic studieswereperformedonneu-
rons differentiated from iPSCs generated from an individual with
TS21 (Park et al., 2008). Additional genotypes were non-diseased
controls (NDCs; Israel et al., 2012),APP duplication (APPdup) (Israel
et al., 2012), APP V717I (Moore et al., 2015), and PSEN1 M146I
(Moore et al., 2015). iPSCs were cultured and maintained feeder-
free in Essential-8 (Life Technologies),without antibiotics.Directed
differentiation of iPSCs to cortical neuronswas performed as previ-
ously described (Shi et al., 2012a, 2012c). Neural stem/progenitor
cells were produced by pooling neural inductions from each iPSC
line. Pooling at this stagewas carried out tominimize experimental
variability among subsequent neuronal differentiations. Neural
stem/progenitor cellswere subsequentlyused for independentneu-
ral differentiations over 15–30 days in parallel to generate postmi-
totic cortical neurons and astrocytes for each experiment and/or
drug treatment. Each separate neuronal differentiationwas consid-
ered a biological replicate. Drug screening was performed on neu-
rons in 96-well plates (Greiner and Ibidi), with some additional
experiments performed in 12-well plates (Corning).Immunocytochemistry
Cell cultures were fixed in 4% (w/v) paraformaldehyde in PBS
and blocked with 5% normal donkey serum in 0.3% (v/v) Tween
20 in Tris-buffered saline before immunofluorescent staining.Primary antibodies used were anti-MAP2 (ab5392, Abcam), anti-
CTIP2 (ab18465, Abcam), and anti-TBR1 (ab31940, Abcam), and
secondary antibodies were Alexa Fluor conjugated. Stained cells
were imaged on an Olympus FV1000 inverted confocal microscope
and data imported into PerkinElmer Volocity for visualization.
Drugs
The Prestwick Chemical library of 1,200 Food and Drug Adminis-
tration-approved compounds was supplied at a concentration of
10 mM in DMSO in a 96-well format (Prestwick Chemical). Addi-
tional compounds used included (R)-flurbiprofen (Cayman), the
g-secretase modulator E2012 (ChemExpress), abamectin (Santa
Cruz Biotechnology), ivermectin (Tocris Biosciences), emamectin
benzoate (Abcam), selamectin (MicroSource Discovery Systems),
moxidectin (Santa Cruz), strychnine HCl (Abcam), picrotoxin
(Tocris), muscimol (Tocris), and the g-secretase inhibitors DAPT
(Sigma) and L-685,458 (Merck-Millipore).
Drug Treatment
For the primary screen, drugs were applied at a final concentration
of 1 mMin0.1%DMSO inneural cell culturemedium. In additional
experiments, drugswere dissolved inDMSOorH2O, and applied to
cells such that final concentrations of DMSO did not exceed 0.4%.
All drug treatments began 50–65 days after the initiation of neural
induction, with media collected and refreshed at 48-hr intervals.
Compound effects were normalized to appropriate vehicle con-
trols within each plate.
Biochemical Assays
Conditionedmedium for biochemical analysis was spun at 8003 g
to remove cellular debris, and supernatant stored at 20C until
use. Measurement of Ab38, Ab40, and Ab42 was performed by
multiplexed immunoassay (Meso Scale Diagnostics), andmeasure-
ment of LDH activity was performed using a Cytotoxicity Detec-
tion kit (Roche).
Immunoprecipitation and Matrix-Assisted Laser
Desorption/Ionization
Conditioned medium for IP-MALDI analysis was centrifuged at
1,200 3 g, and supernatant stored at 80C in protein LoBind
microcentrifuge tubes (Eppendorf) until use. The Ab peptide pro-
file was determined by immunoprecipitation, using Ab-specific
antibodies coupled to magnetic beads, in combination with a
MALDI-TOF/TOF instrument (UltraFleXtreme, Bruker Daltonics)
as described previously (Portelius et al., 2007). Samples were pre-
pared as described previously (Portelius et al., 2007). Of the 25
Ab species identified, it was determined that Ab1-19 was highly
variable between samples within the same treatment groups. As
it has not been identified as a species of interest in previous studies
investigating pharmacologicalmodulation of secretase complexes,
Ab1-19 was excluded from further analysis and its contribution to
total Ab removed.
Immunoblotting
After collection in ice-cold PBS, cells were lysed in RIPA buffer con-
taining 1 mM DTT, protease and phosphatase inhibitors (Pierce),Stem Cell Reports j Vol. 8 j 870–882 j April 11, 2017 879
and 25 U/mL DNAse. The soluble fraction of cell lysates was sub-
jected to SDS-PAGE and immunoblotting. Primary antibodies
used were N-cadherin (610921, BD Transduction Laboratories),
APP (SIG-39152, Covance), and histone H3 (ab1791, Abcam).
Immunoblot detection was performed using the Odyssey Infrared
Imaging System.
Cell-Free g-Secretase Assays
The g-secretase in vitro activity assay was performed as described
previously (Szaruga et al., 2015), with minor modifications. See
Supplemental Experimental Procedures for additional details.
Statistical Analysis
Statistical analysis was performed using IBM SPSS and GraphPad
Prism. Alpha was set to 0.05 for all significance testing. n refers
to the number of independent cultures of iPSC-derived neurons,
except in the case of cell-free experiments where n represents inde-
pendent experiments. See Supplemental Experimental Procedures
for detailed statistical procedures.
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